Compare American Well Corp (AMWL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Moderna, Inc. — how do they compare? American Well Corp trades at $13.01 (market cap $220.94M), while Moderna, Inc. trades at $63.68 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 109.4× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| AMWL | MRNA | |
|---|---|---|
Market Cap | $220.94M | $24.18B |
Sector | Health | Health |
52-Week High | $13.58 | $81.80 |
52-Week Low | $3.78 | $22.36 |
Enterprise Value | $27.98M | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $12.54, down 7.66% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows improving financial trends, with revenue declining to $249.33M in 2025 but net losses narrowing significantly to -$95.70M. Recent Q2 2026 earnings beat expectations, and news highlights strategic developments including a key executive appointment at Amazon's healthcare unit.
The outlook suggests cautious optimism as AMWL progresses toward cash-flow breakeven, supported by analyst coverage leaning Hold. Key risks include persistent revenue declines and high cash burn, though improving margins and reduced losses indicate potential for recovery if execution continues.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
